血清IL-17、IL-32、IL-33、IL-37联合检测对初治多发性骨髓瘤患者早期治疗反应性的预测价值  

Predictive Value of Combined Detection of Serum IL-17,IL-32,IL-33 and IL-37 in Early Treatment Response of Primary Multiple Myeloma Patients

作　　者：苗玉迪[1] 胡星星 李艳春 李程亮 赵乔佳杰 MIAO Yu-di;HU Xing-xing;LI Yan-chun;LI Cheng-liang;ZHAO Qiao-jia-jie(Department of Hematology,Shaanxi Provincial People’s Hospital,Xi'an,Shaanxi,710068,China;Department of Clinical Laboratory,Xi’an International Medical Center Hospital,Xi'an,Shaanxi,710100,China;Department of General Practice,Guangzhou First People’s Hospital,Guangdong,Guangzhou,510180,China;Blood Research Room,Shaanxi Provincial People’s Hospital,Xi'an,Shaanxi,710068,China)

机构地区：[1]陕西省人民医院血液内科,陕西西安710068 [2]西安国际医学中心医院检验科,陕西西安710100 [3]广州市第一人民医院全科医学科,广东广州510180 [4]陕西省人民医院血研室,陕西西安710068

出　　处：《现代生物医学进展》2022年第22期4279-4284,共6页Progress in Modern Biomedicine

基　　金：陕西省社会发展科技攻关项目(2015SF065)。

摘　　要：目的:探讨血清白细胞介素-17(IL-17)、白细胞介素-32(IL-32)、白细胞介素-33(IL-33)、白细胞介素-37(IL-37)联合检测对接受硼替佐米为基础一线治疗方案的初治多发性骨髓瘤(MM)患者早期治疗反应性的预测价值。方法:选择2018年7月至2021年3月期间陕西省人民医院收治的初治MM患者176例为研究对象,所有患者均接受以硼替佐米为基础一线的治疗方案,根据早期治疗反应性分为敏感组(142例)和非敏感组(34例);采用酶联免疫吸附法检测并比较两组血清IL-17、IL-32、IL-33、IL-37水平,并分析其联合检测对早期治疗反应性的预测价值。结果:敏感组治疗前血清IL-17、IL-32水平低于非敏感组,IL-33、IL-37水平高于非敏感组(P<0.05)。多因素logistic回归分析显示,年龄≥65岁、血清IL-17≥29.70 pg/mL、IL-32≥63.02 ng/L、肿瘤分期Ⅲ期是早期治疗反应性的危险因素(P<0.05),IL-33>141.97 pg/mL、IL-37>69.17 ng/L是保护因素(P<0.05)。血清IL-17、IL-32、IL-33、IL-37联合检测预测早期治疗反应性的曲线下面积(AUC)为0.866(95%CI:0.801~0.972)。结论:年龄、肿瘤分期、血清IL-17、IL-32、IL-33、IL-37是MM患者早期治疗反应性的影响因素,联合检测血清IL-17、IL-32、IL-33、IL-37水平对接受硼替佐米为基础一线治疗方案的初治MM患者早期治疗反应性预测价值较高。Objective:To explore the predictive value of the combined detection of serum interleukin-17(IL-17),interleukin-32(IL-32),interleukin-33(IL-33)and interleukin-37(IL-37)in the early treatment response of primary multiple myeloma(MM)patients who received bortezomib based first-line treatment.Methods:176 cases of primary MM patients in our hospital from July 2018 to March2021 were selected as the research object.All patients received bortezomib based first-line treatment.They were divided into sensitive group(142 cases)and non sensitive group(34 cases)according to the early treatment response.The levels of serum IL-17,IL-32,IL-33and IL-37 in the two groups were detected and compared by enzyme-linked immunosorbent assay,and the predictive value of their combined detection for early treatment response was analyzed.Results:Before treatment,the levels of serum IL-17 and IL-32 in sensitive group were lower than those in non sensitive group,and the levels of IL-33 and IL-37 were higher than those in non sensitive group(P<0.05).Multivariate Logistic regression analysis showed that age≥65 years,serum IL-17≥29.70 pg/mL,IL-32≥63.02 ng/L,tumor stageⅢwere the risk factors of early treatment response(P<0.05),IL-33>141.97 pg/mL,IL-37>69.17 ng/L were the protective factors(P<0.05).The area under the curve(AUC)of serum IL-17,IL-32,IL-33 and IL-37 combined detection in predicting early treatment response was 0.866(95%CI:0.801-0.972).Conclusion:Age,tumor stage,serum IL-17,IL-32,IL-33 and IL-37 are the influencing factors of early treatment response in MM patients.Combined detection of the levels of serum IL-17,IL-32,IL-33 and IL-37has a high predictive value for early treatment response in MM patients receiving bortezomib based first-line treatment.

关 键 词：多发性骨髓瘤 IL-17 IL-32 IL-33 IL-37 硼替佐米 治疗反应性 预测价值 

分 类 号：R733.3[医药卫生—肿瘤]